

Quarterly Compliance Report on Corporate Governance

Name of the Company: PARMAX PHARMA LIMITED.

Quarter ending on: 30th June 2015

Particulars	Clause of Listing agreement	Compliance Status Yes/No	Remarks
I Board of Directors	49 I		
(A) Composition of Board	49(IA)	Yes	
(B) Non-executive Directors' compensation & disclosures	49 (IB)	Yes	
(C) Other provisions as to Board and Committees	49 (IC)	Yes	
(D) Code of Conduct	(49 (ID)	Yes	
II. Audit Committee	49 (II)		
(A) Qualified & Independent Audit Committee	49 (IIA)	Yes	
(B) Meeting of Audit Committee		Yes	
(C) Powers of Audit Committee 49 (IIC)	49 (IIB)	Yes	
(D) Role of Audit Committee	49 II(D)	Yes	
(E) Review of Information by Audit Committee	49 (IIE)	Yes	
III. Subsidiary Companies	49 (III)	N.A.	
IV. Disclosures	49 (IV)		
(A) Basis of related party transactions	49 (IV A)	Yes	
(B) Disclosure of Accounting Treatment	49 (IV B)	Yes	
(C) Board Disclosures	49 (IV C)	Yes	
(D) Proceeds from public issues, rights issues, preferential issues etc.	49 (IV D)	N.A.	
(E) Remuneration of Directors	49 (IV E)	Yes	A disclosure on the remuneration of Directors would be a part of section on Corporate Governance in the Annual Report of the Company for the year ended 31 st March, 2016.
(F) Management	49 (IV F)	Yes	Management Discussion & other Analysis would be a part of Annual Report of the Company for the year ended 31 st March, 2016.
(G) Shareholders	49 (IV G)	Yes	" Will be complied with at the AGM"
V.CEO/CFO Certification	49 (V)	Yes	CEO/CFO certification would be apart of Annual Report of the Company for the year ended 31 st March, 2016.
VI. Report on Corporate Governance	49 (VI)	Yes	Report of Corporate Governance would be apart of Annual Report of the Company for the year ended 31 st March, 2016.
VII. Compliance	49 (VII)	Yes	Compliance Certificate from Auditors would be apart of Annual Report of the Company for the year ended 31 st March, 2016.

